Literature DB >> 12181431

Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides.

Thipparat Suwanmanee1, Halina Sierakowska, Giuseppina Lacerra, Saovaros Svasti, Suzanne Kirby, Christopher E Walsh, Suthat Fucharoen, Ryszard Kole.   

Abstract

Correct human beta-globin mRNA has been restored in erythroid cells from transgenic mice carrying the human gene with beta-globin IVS2-654 splice mutation and from thalassemia patients with the IVS2-654/beta(E) genotype. This was accomplished in a dose- and time-dependent manner by free uptake of morpholino oligonucleotide antisense to the aberrant splice site at position 652 of intron 2 in beta-globin pre-mRNA. Under optimal conditions of oligonucleotide uptake, the maximal levels of correct human beta-globin mRNA and hemoglobin A in patients' erythroid cells were 77 and 54%, respectively. These levels of correction were equal to, if not higher than, those obtained by syringe loading of the oligonucleotide into the cells. Comparison of splicing correction results with the cellular uptake of fluorescein-labeled oligonucleotide indicated that the levels of mRNA and hemoglobin A correlate well with the nuclear localization of the oligonucleotide and the degree of erythroid differentiation of cultured cells. Similar but not as pronounced results were obtained after the oligonucleotide treatment of bone marrow cells from IVS2-654 mouse. The effectiveness of the free antisense morpholino oligonucleotide in restoration of correct splicing of IVS2-654 pre-mRNA in cultured erythropoietic cells from transgenic mice and thalassemic patients suggests the applicability of this or similar compounds in in vivo experiments and possibly in treatment of thalassemia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181431     DOI: 10.1124/mol.62.3.545

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  Temperature-dependent splicing of beta-globin pre-mRNA.

Authors:  Federica Gemignani; Peter Sazani; Paul Morcos; Ryszard Kole
Journal:  Nucleic Acids Res       Date:  2002-11-01       Impact factor: 16.971

Review 2.  Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing.

Authors:  Peter Sazani; Ryszard Kole
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

3.  Antisense oligonucleotide-based therapy in human erythropoietic protoporphyria.

Authors:  Vincent Oustric; Hana Manceau; Sarah Ducamp; Rima Soaid; Zoubida Karim; Caroline Schmitt; Arienne Mirmiran; Katell Peoc'h; Bernard Grandchamp; Carole Beaumont; Said Lyoumi; François Moreau-Gaudry; Véronique Guyonnet-Dupérat; Hubert de Verneuil; Joëlle Marie; Herve Puy; Jean-Charles Deybach; Laurent Gouya
Journal:  Am J Hum Genet       Date:  2014-03-27       Impact factor: 11.025

4.  Future alternative therapies for β-thalassemia.

Authors:  Stefano Rivella; Eliezer Rachmilewitz
Journal:  Expert Rev Hematol       Date:  2009-12-01       Impact factor: 2.929

Review 5.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 6.  Therapeutic potential of splice-switching oligonucleotides.

Authors:  John Bauman; Natee Jearawiriyapaisarn; Ryszard Kole
Journal:  Oligonucleotides       Date:  2009-03

7.  Sodium Butyrate and Valproic Acid as Splicing Restoring Agents in Erythroid Cells of β-Thalassemic Patients.

Authors:  Mahmoud Shekari Khaniani; Mahdieh Tagizadeh; Abbasali Hosseinpour Feizi; Sima Mansoori Derakhshan
Journal:  Iran J Biotechnol       Date:  2016-03       Impact factor: 1.671

8.  Alternatively spliced mu opioid receptor C termini impact the diverse actions of morphine.

Authors:  Jin Xu; Zhigang Lu; Ankita Narayan; Valerie P Le Rouzic; Mingming Xu; Amanda Hunkele; Taylor G Brown; William F Hoefer; Grace C Rossi; Richard C Rice; Arlene Martínez-Rivera; Anjali M Rajadhyaksha; Luca Cartegni; Daniel L Bassoni; Gavril W Pasternak; Ying-Xian Pan
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

9.  Modulation of mdm2 pre-mRNA splicing by 9-aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions.

Authors:  Takehiko Shiraishi; Jonhard Eysturskarth; Peter E Nielsen
Journal:  BMC Cancer       Date:  2010-06-30       Impact factor: 4.430

10.  Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA.

Authors:  Damian Ittig; Songkai Liu; Dorte Renneberg; Daniel Schümperli; Christian J Leumann
Journal:  Nucleic Acids Res       Date:  2004-01-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.